According to a recent multicenter study including three different subgroups of NETs (not only GEP-NETs, but also lung NETs, and of unknown origin), the NETest was able to discriminate NETs from a complex set of controls: healthy, non-NET malignancies, and benign diseases responsible for increased Chromogranin A (CgA) levels [16]. The gene discussed is CHGA; the disease is lung neuroendocrine neoplasm.